

<script nonce="622066080" type="text/javascript">
	var write_sceen_time = (+new Date());
</script>

<div id="js_article" class="rich_media">

    <div id="js_top_ad_area" class="top_banner">

    </div>


    <div class="rich_media_inner">
        <div id="page-content">
            <div id="img-content" class="rich_media_area_primary">
                <h2 class="rich_media_title" id="activity-name">
                    【阿斯利康PDL-1招募患者2】比较Durvalumab与标准治疗用于PD-L1高表达晚期非小细胞肺癌一线治疗的III期临床试验
                </h2>
                <div class="rich_media_meta_list">
                    <em id="post-date" class="rich_media_meta rich_media_meta_text">2017-01-20</em>

                    <a class="rich_media_meta rich_media_meta_link rich_media_meta_nickname" href="##" id="post-user">临床试验招募信息</a>
                    <span class="rich_media_meta rich_media_meta_text rich_media_meta_nickname">临床试验招募信息</span>

                    <div id="js_profile_qrcode" class="profile_container" style="display:none;">
                        <div class="profile_inner">
                            <strong class="profile_nickname">临床试验招募信息</strong>
                            <img class="profile_avatar" id="js_profile_qrcode_img" src="" alt="">

                            <p class="profile_meta">
                                <label class="profile_meta_label">WeChat ID</label>
                                <span class="profile_meta_value">ClinicalTrials_Info</span>
                            </p>

                            <p class="profile_meta">
                                <label class="profile_meta_label">Intro</label>
                                <span class="profile_meta_value">帮您更方便、更快捷的了解正在开展的临床试验招募信息！</span>
                            </p>

                        </div>
                        <span class="profile_arrow_wrp" id="js_profile_arrow_wrp">
                                <i class="profile_arrow arrow_out"></i>
                                <i class="profile_arrow arrow_in"></i>
                            </span>
                    </div>
                </div>


                <div class="rich_media_content " id="js_content">


                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="line-height: 150%; color: red;">1.<span
                            style="font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
                            style="line-height: 150%; font-family: 宋体; color: red;">试验药物简介</span></span></p>
                    <p style="text-indent:28px;line-height:150%"><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; background: white;">Durvalumab（MEDI4736）是抗PDL-1单克隆抗体；</span>
                    </p>
                    <p style="text-indent:28px;line-height:150%"><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; background: white;">本试验适应症是晚期非小细胞肺癌。</span>
                    </p>
                    <p style="text-indent:28px;line-height:150%"><span style="line-height: 150%; font-size: 12px;">&nbsp;</span>
                    </p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; color: red;">2.<span
                            style="font-stretch: normal; font-size: 9px; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red;">试验目的</span></span>
                    </p>
                    <p style="text-indent:28px;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: rgb(83, 83, 83); background: white;">评估</span><span
                            style="font-size: 12px; line-height: 150%; color: rgb(83, 83, 83); background: white;">durvalumab</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: rgb(83, 83, 83); background: white;">相比标准治疗在下列参数的有效性：无进展生存期、总生存期</span></span>
                    </p>
                    <p style="text-indent:28px;line-height:150%"><span
                            style="line-height: 150%; font-size: 12px; background: white;">&nbsp;</span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; color: red;">3.<span
                            style="font-stretch: normal; font-size: 9px; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red;">试验设计</span></span>
                    </p>
                    <p style="line-height:150%"><span style="line-height: 150%; font-family: 宋体; font-size: 12px;">试验分类：安全性和有效性</span>
                    </p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">试验分期：</span><span
                            style="font-size: 12px; line-height: 150%;"> III</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">期</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red;">设计类型：平行分组（试验组：</span><span
                            style="font-size: 12px; line-height: 150%; color: red;"> <span
                            style="font-size: 12px; background: white;">Durvalumab</span></span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red; background: white;">，</span><span
                            style="font-size: 12px; line-height: 150%; color: red; background: white;">2.</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red; background: white;">紫杉醇</span><span
                            style="font-size: 12px; line-height: 150%; color: red; background: white;">/</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red; background: white;">培美曲塞</span><span
                            style="font-size: 12px; line-height: 150%; color: red; background: white;">/</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red; background: white;">吉西他滨</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red;">）</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">随机化：</span><span
                            style="font-size: 12px; line-height: 150%;"> &nbsp;&nbsp;</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">随机化</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">盲法：</span><span
                            style="font-size: 12px; line-height: 150%;">&nbsp; &nbsp; &nbsp;&nbsp;</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">开放</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">试验范围：国际多中心试验</span><span
                            style="font-size: 12px; line-height: 150%;"> </span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">试验人数：</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: rgb(83, 83, 83); background: white;">总体440人， 中国352人</span></span>
                    </p>
                    <p style="line-height:150%"><span style="line-height: 150%; font-family: 宋体; font-size: 12px;">&nbsp;</span>
                    </p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; color: red;">4.<span
                            style="font-stretch: normal; font-size: 9px; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red;">入选标准</span></span>
                    </p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">1 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">筛选时，年龄≥</span><span
                            style="font-size: 12px; line-height: 150%;">18</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">岁。</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">2 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">在进行任何方案相关流程之前</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">包括</span><span
                            style="font-size: 12px; line-height: 150%;">PD-L1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">检测和其他筛选评估</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">，从患者</span><span
                            style="font-size: 12px; line-height: 150%;">/</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">法定代表获得书面知情同意。</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">3 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">组织学或细胞学确认的</span><span
                            style="font-size: 12px; line-height: 150%;">IV</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">期非小细胞肺癌</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">根据国际肺癌研究协会胸部肿瘤分期手册第</span><span
                            style="font-size: 12px; line-height: 150%;">7</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">版；</span><span
                            style="font-size: 12px; line-height: 150%;">IASLC StagingManual in Thoracic Oncology)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">4 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">患者肿瘤必须缺乏</span><span
                            style="font-size: 12px; line-height: 150%;">EGFR</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">敏感突变</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">即外显子</span><span
                            style="font-size: 12px; line-height: 150%;">19</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">缺失，或外显子</span><span
                            style="font-size: 12px; line-height: 150%;">21 L858R</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、外显子</span><span
                            style="font-size: 12px; line-height: 150%;">21 L861Q</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、外显子</span><span
                            style="font-size: 12px; line-height: 150%;">18 G719X</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">或外显子</span><span
                            style="font-size: 12px; line-height: 150%;">20 S7681</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">突变</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">和</span><span
                            style="font-size: 12px; line-height: 150%;">ALK</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">重排。</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">5 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">随机分组之前，患者必须具有肿瘤细胞</span><span
                            style="font-size: 12px; line-height: 150%;">PD-L1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">高表达状态</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">新鲜标本或</span><span
                            style="font-size: 12px; line-height: 150%;">3</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">个月内的归档样本</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">6 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">入组时，东部肿瘤协作组</span><span
                            style="font-size: 12px; line-height: 150%;">(ECOG)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">体力状态评分为</span><span
                            style="font-size: 12px; line-height: 150%;">0</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">或</span><span
                            style="font-size: 12px; line-height: 150%;">1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">7 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">至少</span><span
                            style="font-size: 12px; line-height: 150%;">1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">个病灶</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">既往未接受过放疗</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">，基线时经</span><span
                            style="font-size: 12px; line-height: 150%;">CT</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">或</span><span
                            style="font-size: 12px; line-height: 150%;">MRI</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">准确测量显示其最长直径≥</span><span
                            style="font-size: 12px; line-height: 150%;">10mm(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">淋巴结除外，淋巴结的短轴必须≥</span><span
                            style="font-size: 12px; line-height: 150%;">15mm)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">，且依照</span><span
                            style="font-size: 12px; line-height: 150%;">RECIST v1.1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">指南，该病灶适合反复准确测量。</span><span
                            style="font-size: 12px; line-height: 150%;"> </span></span></p>
                    <p style="line-height:150%"><br/></p>
                    <p style="line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; color: red;">5.<span
                            style="font-stretch: normal; font-size: 9px; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red;">排除标准</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">1 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">既往接受过化疗或任何其他系统性治疗的晚期</span><span
                            style="font-size: 12px; line-height: 150%;">NSCLC</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。如果疾病进展发生在末次治疗</span><span
                            style="font-size: 12px; line-height: 150%;">6</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">个月后，则既往接受含铂辅助化疗、新辅助化疗或针对性放化疗治疗局部晚期疾病的患者，也有资格入组研究。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">2 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">先前暴露于免疫介导治疗，包括但不限于其他抗</span><span
                            style="font-size: 12px; line-height: 150%;">CTLA-4</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、抗</span><span
                            style="font-size: 12px; line-height: 150%;">PD-1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、抗</span><span
                            style="font-size: 12px; line-height: 150%;">PD-L1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">和抗细胞程序性死亡配体</span><span
                            style="font-size: 12px; line-height: 150%;">2(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">抗</span><span
                            style="font-size: 12px; line-height: 150%;">-PD-L2)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">抗体，不包括治疗性抗肿瘤疫苗。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">3 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">在研究药物首次给药</span><span
                            style="font-size: 12px; line-height: 150%;">4</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">周内，放射治疗累及超过</span><span
                            style="font-size: 12px; line-height: 150%;">30%</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">的骨髓或大范围放射治疗。注：对于孤立病灶的局部治疗</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">不包括靶病灶</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">是可以接受的。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">4 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">脑转移或脊髓压迫，除非患者病情稳定</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">无症状，无证据显示新发或正在出现的脑转移</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">及在研究治疗开始之前停止类固醇药物治疗至少</span><span
                            style="font-size: 12px; line-height: 150%;">14</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">天。在放疗和</span><span
                            style="font-size: 12px; line-height: 150%;">/</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">或手术后，有脑转移的患者在干预治疗后必须等待</span><span
                            style="font-size: 12px; line-height: 150%;">4</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">周，且必须在随机分组前通过影像学确认稳定。筛查时发现疑似脑转移的患者应在入组研究前行脑部</span><span
                            style="font-size: 12px; line-height: 150%;">CT/MRI</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">检查。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">5 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">有软脑脊膜癌病史。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">6 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">组织学类型为小细胞肺癌和</span><span
                            style="font-size: 12px; line-height: 150%;">NSCLC</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">混合型、肺肉瘤样癌。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">7 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">血红蛋白</span><span
                            style="font-size: 12px; line-height: 150%;">&lt;9.0g/dL</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">8 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">绝对中性粒细胞计数</span><span
                            style="font-size: 12px; line-height: 150%;">&lt;1.5</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">×</span><span
                            style="font-size: 12px; line-height: 150%;">109/L</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">9 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">血小板计数</span><span
                            style="font-size: 12px; line-height: 150%;">&lt;100</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">×</span><span
                            style="font-size: 12px; line-height: 150%;">109/L</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">10 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">血清胆红素＞</span><span
                            style="font-size: 12px; line-height: 150%;">1.5</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">×</span><span
                            style="font-size: 12px; line-height: 150%;">ULN</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。这将不适于已证实患有</span><span
                            style="font-size: 12px; line-height: 150%;">Gilbert</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">综合征的患者，这类患者可向医生咨询。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">11 ALT</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">和</span><span
                            style="font-size: 12px; line-height: 150%;">AST</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">＞</span><span
                            style="font-size: 12px; line-height: 150%;">2.5</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">×</span><span
                            style="font-size: 12px; line-height: 150%;">ULN</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">；对于肝转移患者：</span><span
                            style="font-size: 12px; line-height: 150%;">ALT</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">和</span><span
                            style="font-size: 12px; line-height: 150%;">AST</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">＞</span><span
                            style="font-size: 12px; line-height: 150%;">5</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">×</span><span
                            style="font-size: 12px; line-height: 150%;">ULN</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">12 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">采用</span><span
                            style="font-size: 12px; line-height: 150%;">Cockcroft-Gault</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">公式或</span><span
                            style="font-size: 12px; line-height: 150%;">24</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">小时采集尿液计算的肌酐清除率</span><span
                            style="font-size: 12px; line-height: 150%;">&lt;50mL/min(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">使用实际体重</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">13 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">使用</span><span
                            style="font-size: 12px; line-height: 150%;">Fridericia</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">公式校正的</span><span
                            style="font-size: 12px; line-height: 150%;">QT</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">间期均值</span><span
                            style="font-size: 12px; line-height: 150%;">(QTcF)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">≥</span><span
                            style="font-size: 12px; line-height: 150%;">470ms</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">14 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">研究治疗前，在最近</span><span
                            style="font-size: 12px; line-height: 150%;">3</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">年内患有活动性或既往自身免疫性疾病或炎性疾病</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">包括炎症性肠病</span><span
                            style="font-size: 12px; line-height: 150%;">[</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">例如结肠炎或克罗恩病</span><span
                            style="font-size: 12px; line-height: 150%;">]</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、憩室炎</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">憩室病除外</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、腹泻相关的腹部疾病或其他严重胃肠道慢性疾病</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、系统性红斑狼疮、结节病或</span><span
                            style="font-size: 12px; line-height: 150%;">Wegener</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">综合征</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">肉芽肿伴血管炎</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、格雷夫斯病、类风湿性关节炎、垂体炎、葡萄膜炎等。对于这一标准，以下情况例外：白癜风或脱发患者；</span><span
                            style="font-size: 12px; line-height: 150%;">- </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">激素替代治疗且病情稳定的甲状腺功能减退患者</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">如桥本综合症病后</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、或不需要全身治疗的银屑病患者。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">15 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">活动性原发性免疫缺陷病史。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">16 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">活动性感染，包括结核病</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">临床评估</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、乙肝、丙肝或人免疫缺陷病毒</span><span
                            style="font-size: 12px; line-height: 150%;">(HIV</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">，阳性</span><span
                            style="font-size: 12px; line-height: 150%;">HIV 1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">或</span><span
                            style="font-size: 12px; line-height: 150%;">2</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">抗体</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。活动性乙肝病毒</span><span
                            style="font-size: 12px; line-height: 150%;">(HBV)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">指的是已知</span><span
                            style="font-size: 12px; line-height: 150%;">HBV</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">表面抗原</span><span
                            style="font-size: 12px; line-height: 150%;">(HBsAg)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">阳性结果。过去有</span><span
                            style="font-size: 12px; line-height: 150%;">HBV</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">感染或消退</span><span
                            style="font-size: 12px; line-height: 150%;"> (</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">指的是存在乙肝核心抗体，但是</span><span
                            style="font-size: 12px; line-height: 150%;">HBsAg</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">缺失</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">的患者符合资格。丙肝病毒</span><span
                            style="font-size: 12px; line-height: 150%;">(HCV)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">抗体阳性的患者只有当</span><span
                            style="font-size: 12px; line-height: 150%;">HCV</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">核糖核酸</span><span
                            style="font-size: 12px; line-height: 150%;">(RNA)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">聚合酶链式反应为阴性时才符合资格。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">17 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">在</span><span
                            style="font-size: 12px; line-height: 150%;">durvalumab</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">首次给药前</span><span
                            style="font-size: 12px; line-height: 150%;">14</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">天内，正在或既往使用免疫抑制药物。对于这一标准，以下情况例外：鼻内吸入性局部类固醇治疗或局部类固醇注射</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">如关节腔内注射</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。未超过</span><span
                            style="font-size: 12px; line-height: 150%;">10mg/</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">天泼尼松或其等效生理剂量的全身皮质类固醇治疗。类固醇素作为过敏反应的预防用药</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">如</span><span
                            style="font-size: 12px; line-height: 150%;">CT</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">前用药</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">18 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">在</span><span
                            style="font-size: 12px; line-height: 150%;">IP</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">首次给药之前</span><span
                            style="font-size: 12px; line-height: 150%;">30</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">天内接受过减毒活疫苗。注：如果患者入组研究，在研究期间和</span><span
                            style="font-size: 12px; line-height: 150%;">IP</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">末次给药后</span><span
                            style="font-size: 12px; line-height: 150%;">30</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">天内不应接受活疫苗。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">19 IP</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">首次给药前</span><span
                            style="font-size: 12px; line-height: 150%;">28</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">天内接受过大型外科手术</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">由研究者定义</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。注：以姑息治疗为目的，对于孤立病灶的局部手术治疗是可以接受的。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">20 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">异体器官移植史。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">21 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">其他原发性恶性肿瘤病史，除了</span><span
                            style="font-size: 12px; line-height: 150%;">:</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">已根治的恶性肿瘤，且在研究药物首次用药前≥</span><span
                            style="font-size: 12px; line-height: 150%;">5</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">年无已知的活动性疾病并且复发的潜在风险极低</span><span
                            style="font-size: 12px; line-height: 150%;">;</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">经充分治疗且无疾病证据的非黑色素瘤皮肤癌或恶性雀斑样痣</span><span
                            style="font-size: 12px; line-height: 150%;">;</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">经充分治疗且无疾病证据的原位癌，如宫颈原位癌。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">22 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">含铂</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">顺铂或卡铂</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">双药化疗的医疗禁忌症。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">23 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">对于绝经前女性患者，尿液或血清妊娠检查结果为阳性。女性在无替代医学原因的情况下停经</span><span
                            style="font-size: 12px; line-height: 150%;">12</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">个月被认为绝经。根据年龄的要求如下：如果</span><span
                            style="font-size: 12px; line-height: 150%;">&lt;50</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">岁的女性在停止外源性激素治疗后停经</span><span
                            style="font-size: 12px; line-height: 150%;">12</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">个月或以上，并且其黄体化激素、卵泡刺激素水平在公认的绝经后范围内或接受过手术绝育术</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">双侧卵巢切除术或子宫切除术</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">，则可视为绝经女性。如果≥</span><span
                            style="font-size: 12px; line-height: 150%;">50</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">岁的女性在停止所有外源性激素治疗后停经</span><span
                            style="font-size: 12px; line-height: 150%;">12</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">个月或以上，或者放疗诱导卵巢切除术并且末次月经发生在</span><span
                            style="font-size: 12px; line-height: 150%;">&gt;1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">年之前，或者化疗诱导停经并且末次月经至今</span><span
                            style="font-size: 12px; line-height: 150%;">&gt;1</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">年，或者接受过手术绝育术</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">双侧卵巢切除术或子宫切除术</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">，则可被视为绝经女性。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">24 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">孕期或哺乳期女性患者，或从筛选到</span><span
                            style="font-size: 12px; line-height: 150%;">durvalumab</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">末次给药后</span><span
                            style="font-size: 12px; line-height: 150%;">90</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">天期间不愿采取高效节育措施且具有生育潜力的男性或女性患者。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">25 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">已知对</span><span
                            style="font-size: 12px; line-height: 150%;">IP</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">、任何辅料或其他人源</span><span
                            style="font-size: 12px; line-height: 150%;">mAbs</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">过敏或有超敏反应。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">26 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">参与本项研究的规划和</span><span
                            style="font-size: 12px; line-height: 150%;">/</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">或开展</span><span
                            style="font-size: 12px; line-height: 150%;">(AstraZeneca</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">工作人员和</span><span
                            style="font-size: 12px; line-height: 150%;">/</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">或在研究中心的工作人员均适用</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">。</span></span></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">27 </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">同时入组于另一项临床研究，除非这是一项观察性</span><span
                            style="font-size: 12px; line-height: 150%;">(</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">非干预性</span><span
                            style="font-size: 12px; line-height: 150%;">)</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体;">临床研究或是一项干预性研究的随访阶段。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%;">28</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; background: white;">根据研究者判断，认为会干扰</span><span
                            style="font-size: 12px; line-height: 150%; background: white;">IP</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; background: white;">评价或患者安全性或研究结果解读的任何情况，包括但不限于：正持续的或活动性感染、充血性心衰征兆、不受控制的高血压、不稳定型心绞痛、心律失常、间质性肺病或符合以下特征的精神疾病</span><span
                            style="font-size: 12px; line-height: 150%; background: white;">/</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; background: white;">社会状况：限制研究要求依从性，显著增加</span><span
                            style="font-size: 12px; line-height: 150%; background: white;"> durvalumab</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; background: white;">引起</span><span
                            style="font-size: 12px; line-height: 150%; background: white;">AE</span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; background: white;">的风险，或影响患者提供知情同意书的能力。</span></span>
                    </p>
                    <p style="text-indent:0;line-height:150%"><br/></p>
                    <p style="text-indent:0;line-height:150%"><span style="font-size: 12px;"><span
                            style="font-size: 12px; line-height: 150%; color: red;">6.&nbsp; </span><span
                            style="font-size: 12px; line-height: 150%; font-family: 宋体; color: red;">研究者信息</span></span>
                    </p>
                    <table cellspacing="1" cellpadding="0" width="725" data-sort="sortDisabled">
                        <tbody>
                        <tr>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" width="55"><p
                                    style="text-align:center"><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">序号</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" width="331">
                                <p style="text-align:center"><span
                                        style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">机构名称</span>
                                </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" width="105">
                                <p style="text-align:center"><span
                                        style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">主要研究者</span>
                                </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" width="49"><p
                                    style="text-align:center"><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">国家</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" width="78"><p
                                    style="text-align:center"><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">省（州）</span></p>
                            </td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" width="54"><p
                                    style="text-align:center"><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">城市</span></p></td>
                        </tr>
                        <tr style=";height:30px">
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="64"><p style="text-align:center"><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">1</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="331"><p><span style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">上海市胸科医院</span>
                            </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="113"><p><span style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">陆舜</span>
                            </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="58"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">中国</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="85"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">上海</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="62"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">上海</span></p></td>
                        </tr>
                        <tr style=";height:30px">
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="70"><p style="text-align:center"><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">2</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="313"><p><span style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">广东省人民医院</span>
                            </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="115"><p><span style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">杨衿记</span>
                            </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="65"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">中国</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="88"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">广东</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="68"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">广州</span></p></td>
                        </tr>
                        <tr style=";height:30px">
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="74"><p style="text-align:center"><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">3</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="303"><p><span style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">大坪医院</span>
                            </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="114"><p><span style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">何勇</span>
                            </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="69"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">中国</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="89"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">四川</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="72"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">重庆</span></p></td>
                        </tr>
                        <tr style=";height:30px">
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="75"><p style="text-align:center"><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">4</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="299"><p><span style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">杭州市第一人民医院</span>
                            </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="112"><p><span style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">马胜林</span>
                            </p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="72"><p><span
                                    style="font-family: 宋体; color: rgb(83, 83, 83); font-size: 12px;">中国</span></p></td>
                            <td style="padding: 5px; border-color: rgb(221, 221, 221); background: white;" height="30"
                                width="89